A supplemental application for Keytruda (pembrolizumab) received FDA approval for efficacy on January 8, 2020. This approval expands the therapeutic applications for the drug, which is sponsored by MERCK SHARP DOHME.
Background
Pembrolizumab, marketed as Keytruda, is an established immunotherapy. As a supplemental approval for efficacy, this indicates an expansion of its previously approved uses. Such approvals typically mean the drug has demonstrated clinical benefit in new or broader patient populations or indications.
What this means
The FDA's supplemental approval for Keytruda's efficacy means that the drug has demonstrated significant clinical benefit in an additional indication or patient population, based on a review of submitted data. This expansion allows healthcare providers to prescribe pembrolizumab for a newly approved use, potentially offering a new or improved treatment option for patients who previously had limited choices. For researchers, this approval reinforces the drug's established profile as an effective immunotherapy and may inform future studies into its mechanism and application across various cancers, potentially leading to further advancements in oncology.
Source
This information was sourced from the U.S. Food and Drug Administration (FDA) website, specifically from the overview page for Biologics License Application (BLA) 125514. The supplemental approval (S-66) for efficacy was granted on January 8, 2020, and is available on accessdata.fda.gov.